Market capitalization | $619.27m |
Enterprise Value | $487.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.48 |
P/S ratio (TTM) P/S ratio | 6.96 |
P/B ratio (TTM) P/B ratio | 1.77 |
Revenue growth (TTM) Revenue growth | -8.18% |
Revenue (TTM) Revenue | $89.04m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
9 Analysts have issued a REGENXBIO, Inc. forecast:
9 Analysts have issued a REGENXBIO, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -263 -263 |
6%
6%
|
|
Depreciation and Amortization | 17 17 |
34%
34%
|
|
Stock Compensation | 40 40 |
1%
1%
|
|
Operating Cash Flow | -218 -218 |
5%
5%
|
|
Investments | 9.96 9.96 |
68%
68%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -228 -228 |
4%
4%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Head office | United States |
CEO | Curran Simpson |
Employees | 344 |
Founded | 2008 |
Website | www.regenxbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.